Search

everythinglearnresearchcommunity

for

Search:↓

User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

User uses 1ml RU58841 with 5ml stemoxydine for scalp coverage. Wants to switch to pyrilutamide and asks about mixing it with other compounds.

Exploring the potential of latanoprost as a hair loss treatment in combination with minoxidil and finasteride.

People are discussing JXL-069 (PP405) for hair loss, with some experimenting with a 0.05% topical gel. Concerns about safety and efficacy persist due to limited testing and lack of official approval.

The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.

A human trial of verteporfin, a drug that can inhibit wound healing by scarring and promote regeneration of original tissue and hair follicles to provide an unlimited source for hair transplants; people discussed the potential of this drug and how it could be rolled out in mainstream with more doctors getting on board.

The conversation is about users trying to regain access to a Discord server related to pp405 research, with differing opinions on the effectiveness of pp405 for hair loss. Specific treatments like Minoxidil, finasteride, and RU58841 are not mentioned in the conversation.

A user is seeing good results with RU58841 for hair loss, noting reduced shedding and thicker hair. They plan to use pumpkin seed oil as a solvent to avoid water content, which they believe reduces the effectiveness of anti-androgens.

The user is hesitant to use finasteride due to potential hormonal side effects and is waiting for the release of pyrilutamide, a new hair loss treatment. Other users suggest trying finasteride, warning about potential regret if hair loss progresses in the meantime.

A discount code for 20% off at Anageninc is shared, valid for purchasing RU58841 or Pyri from May 10-11, 2025. The conversation focuses on hair loss treatments using RU58841.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

A 46-year-old male shared his 3-week progress using HIMS serum with Finasteride 0.3% and Minoxidil 6%, showing improvement without noticeable shedding. His routine includes vitamins, a healthy diet, and specific hair care practices like microneedling and using caffeine solution.

Hair loss treatments, with users discussing their experiences with both RU58841 and Pyrilutamide, noting that the latter has only recently become available but may yield better results in the long term.

The user mixes their own RU58841 solution and found that increasing the ethanol content improved absorption and reduced scalp itching. A study on minoxidil showed that penetration increased with higher ethanol concentrations, reaching maximum penetration at 90% ethanol.

The conversation discusses impressive results from a 28-day application of a hair loss treatment. Users compare it to their experiences with Minoxidil and Dutasteride, noting excitement over the new findings.

A dermatologist advised a patient to stop taking finasteride (fin) after turning 40 due to potential risk of aggressive prostate cancer. The patient and others in the conversation debated this advice, discussing the relationship between finasteride, prostate cancer, and hair loss, and considering alternatives like topical finasteride.

A hair restoration case involved injecting four different doses of Verteporfin into the mid scalp and using Scalp MicroPigmentation (SMP) around the extraction areas. Photos were taken and an update will be shared soon.

The conversation is about making a 20mg/ml RU58841 solution for hair loss treatment using ethanol and propylene glycol. The user receives advice on calculating the correct amount of RU58841 powder needed.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Verteporfin considered for treating donor areas after hair transplants.

PP-405, a potential hair loss treatment, shows promise in stimulating dormant hair follicles and may help with various hair loss types. Current treatments like Minoxidil are still recommended as PP-405 is in early trials and may take years to become available.

Visible hair improvement after 10 weeks using minoxidil, estradiol enanthate, acetophenide algestone, and bicalutamide. The user is a 25-year-old male with reduced testosterone levels, expressing a preference for less masculinity.

A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.

A group buy for hair loss treatments including Harmine 19a, TM5614, Abiraterone Acetate, and others. A compound, BMS-202, that can potentially reverse gray hair is also mentioned.

VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.

RU58841 slowed hair loss for a DUPA sufferer after other treatments like finasteride, dutasteride, and minoxidil failed. Some users reported side effects with RU58841, while others did not experience any.

The user started using pyrilutamide for hair loss on January 24, applying 1ml daily without other treatments, and after 10 days noticed reduced hair shedding and improved hair quality, with plans to continue for at least 6 months. They experienced chest pain initially, which could be related to starting methylphenidate or pyrilutamide, but the pain has since subsided.

PP405 may revive dormant hair follicles but is unlikely to help with long-term baldness where follicles are replaced by scar tissue. It is seen as a potential adjunct to treatments like minoxidil and finasteride, but its effectiveness on deeply fibrotic or scarred areas is doubtful.